Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (AMRS) is frequently featured in news coverage for its activities as a vertically integrated synthetic biology company focused on sustainable ingredients produced via precision fermentation. Company announcements highlight developments across its Lab-to-Market™ technology platform, industrial biomanufacturing assets, strategic partnerships, and financial and operational restructuring efforts.
News about Amyris often covers its strategic transformation initiatives, including programs aimed at cost reduction, portfolio simplification, and changes to its capital structure and liquidity. The company has publicly discussed a transformation program supported by external advisors, as well as the establishment of internal governance structures to oversee these efforts. A significant news event was the commencement of voluntary Chapter 11 proceedings by Amyris and certain domestic subsidiaries, described as a step to facilitate an operational and financial restructuring centered on its core sustainable ingredients business.
Investors and observers can also find updates on Amyris’ industrial biotechnology operations, such as its precision fermentation plant in Barra Bonita, Brazil. Recent news includes Amyris taking full ownership of this plant, investing in additional fermentation capacity, and winding down a joint venture while retaining manufacturing assets and royalty interests related to specific fermented ingredients.
Another recurring theme in Amyris news is the formation and evolution of strategic partnerships and licensing agreements. Press releases describe exclusive licenses for cosmetic ingredients, long-term manufacturing agreements, and collaborations for sustainable squalene and fermented sweetener technologies. Earnings updates and revenue guidance communications provide additional context on how these partnerships, ingredient sales, and technology access activities fit into the company’s broader strategic agenda.
This news page aggregates such company-issued releases and related coverage, offering a centralized view of key developments in Amyris’ synthetic biology, fermentation, partnership, and restructuring activities over time.
Amyris, a leader in synthetic biotechnology, will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 14, 2020, at 10:00 a.m. ET. CEO John Melo will discuss the company's performance and progress, with a live webcast available on its investor relations website. Amyris specializes in sustainable ingredients for Clean Health and Beauty markets, owning three consumer brands: Biossance, Pipette, and Purecane. The presentation will not include a Q&A session.
Amyris, Inc. (Nasdaq: AMRS) has successfully scaled up the commercial production of Cannabigerol (CBG) using its fermentation process. The company expects to deliver one ton of high purity CBG this year, anticipating first commercial revenue from its sale. CBG, known for its therapeutic potential, is produced at a lower cost with higher purity than traditional methods. Amyris reports that CBG shows superior efficacy in topical applications compared to CBD. This marks the tenth product developed at scale through its biotechnology platform, underscoring its growth strategy in sustainable ingredient production.
Amyris, Inc. (Nasdaq: AMRS) has appointed Sheila Shekar Pollak as the new Chief Marketing Officer for its Biossance™ Clean Beauty skincare brand. Pollak, with a strong background in brand strategy from her prior role at Athleta, aims to enhance the growth and brand value of Biossance. CEO John Melo expressed confidence in Pollak's ability to drive sales, which are anticipated to reach record highs this quarter. Pollak is excited to align her sustainability-focused vision with Biossance's commitment to clean beauty.
Amyris, Inc. (Nasdaq: AMRS) announces its Q2 2020 financial results, achieving a record revenue of $26 million in Consumer & Ingredients, more than doubling year-over-year. The company completed a $200 million private placement, reducing debt by $121 million (40%) since the start of 2020, which will lower cash servicing costs by $30 million in H2 2020. EBITDA improved, with cash operating expenses dropping to $43 million, the lowest in five quarters. Amyris signed partnerships for Purecane™ in baking and an RNA vaccine platform.
Amyris has partnered with the Infectious Disease Research Institute (IDRI) to develop a COVID-19 RNA vaccine using its sustainable fermentation technology. This collaboration aims to create semi-synthetic squalene-based adjuvants, enhancing vaccine efficacy while addressing supply issues related to traditional shark-derived squalene. IDRI's innovative RNA vaccine platform is anticipated to offer significant advantages over existing vaccines. The companies expect to commercialize their adjuvant by end of this year, with potential for a vaccine by next year, emphasizing their commitment to tackling global pandemics.
Amyris, a leader in synthetic biotechnology, will host a conference call on August 6, 2020, at 6:00 a.m. PT to discuss its second quarter 2020 results. The financial results will be released in the morning before the call. Key executives, including CEO John Melo and CFO Han Kieftenbeld, will provide insights into the company’s financial performance and future strategy. Interested parties can join the call by dialing (888) 567-1603 or accessing a live webcast at the company’s website.
On July 15, 2020, Amyris announced the launch of Biosilica™, a sustainable plant-derived silica sourced from sugarcane ashes. This innovation, commercialized by Aprinnova, offers an eco-friendly alternative to traditional silica, often derived from non-renewable resources. Biosilica™ is intended for use in various cosmetic products and aims to meet the growing consumer demand for clean beauty ingredients. Consumer studies indicate improved performance in cosmetics made with Biosilica™ compared to conventional silica. The ingredient will be available for sampling in August, with commercial volumes expected to roll out in 2021.
Biossance, a clean skincare brand from Amyris (Nasdaq: AMRS), has launched The Clean Academy Impact Award to recognize sustainability leaders. The initiative debuted on June 29, 2020, during a digital event, with winners receiving $10,000 and mentorship. U.S. residents aged 18 and above can apply by July 29, 2020. The award aims to support projects focused on ocean protection, in partnership with Oceana. Biossance promotes sustainable practices, utilizing vegan squalane derived from sugarcane, and aligns with Oceana's mission to restore marine biodiversity.